Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Pet Cancer Therapeutics Market

Pet Cancer Therapeutics Market Trends

Report ID: GMI2017
Published Date: Dec 2024
Report Format: PDF

Download Free Sample

Pet Cancer Therapeutics Market Trends

Advancements in veterinary oncology are driving market growth by introducing innovative and targeted treatments that improve outcomes in pet cancer care. Developments such as precision therapies, advanced diagnostics, and immunotherapy offer more effective and less invasive options, leading to improved survival rates for pets with cancer. This progress is significantly contributing to the overall expansion of the market.

For instance, in October 2024, Calviri, a biotech firm specializing in cancer vaccines for dogs and humans, has initiated a clinical trial for its investigational immunotherapy vaccine in canines with early-stage hemangiosarcoma (HSA). The Scout Out Canine Hemangiosarcoma (SOCH) study aimed to assess whether the "pre-made" vaccine, combined with standard treatments like surgery and chemotherapy, can extend the lifespan of dogs with stage 1 or 2 HSA by stimulating the immune system to target cancer cells. This trial launch aimed to lead to significant advancements in canine cancer care.
Moreover, factors such as high treatment costs, regulatory hurdles, a shortage of specialized veterinary professionals, and limited awareness in developing regions are expected to hinder the market's growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The pet cancer therapeutics industry was valued at USD 477.1 million in 2024 and is estimated to grow at a 9.7% CAGR from 2025 to 2034, driven by the increasing trend of pet humanization.

The dog segment dominated the market with a valuation of USD 402 million in 2024 due to the higher incidence of cancer in dogs compared to other pets.

The U.S. held a significant position in the North American pet cancer therapeutics market in 2024 and is projected to dominate with a 9.3% CAGR throughout the forecast period, supported by advanced veterinary healthcare infrastructure and high pet ownership rates.

Key players in the industry include AB Science, Boehringer Ingelheim International, CureLab Oncology, Dechra Pharmaceuticals, Elanco Animal Health, ELIAS Animal Health, NovaVive, Qbiotics, Pfizer, Torigen, and Vibrac.